Skip to main content

Molly Henderson

Equibles does not estimate personal net worth.

About Molly Henderson

Earlier roles on record: CFO at UroGen Pharma Ltd. (URGN) until March 25, 2022. UroGen Pharma Ltd. reported in an 8-K filed March 21, 2022 that Molly Henderson resigned as Chief Financial Officer, effective March 25, 2022. The proxy statement of UroGen Pharma Ltd. reports total compensation of $904,759 for Molly Henderson in fiscal 2021, including a base salary of $434,113. Disclosed compensation is on record for 2 fiscal years. Molly Henderson has spoken on 6 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on March 21, 2022. The companies whose calls Molly Henderson spoke on are classified in the Healthcare sector.

“On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.”
UroGen Pharma Ltd. Form 8-K, filed March 21, 2022 · Read the filing

Molly Henderson on recent calls

“Before reviewing our fourth quarter and year-end 2021 financial results, I'd like to touch upon the up to $100 million non-dilutive term loan financing we have recently announced with funds managed by Pharmakon Advisors.”
CFO, UroGen Pharma Ltd. Q4 FY2021 Earnings Call ·
“UroGen recorded net product sales of Jelmyto for the third quarter ended September 30, 2021 of approximately $11.4 million, aggregating to $31.9 million for the first nine months of 2021.”
CFO, UroGen Pharma Ltd. Q3 FY2021 Earnings Call ·
“And thank you to everyone for joining today's call. As mentioned by Liz and Jeff, we recorded net product sales of Jelmyto for the second quarter 2021 of approximately $13 million, and $20.5 million for the first-half of 2021.”
CFO, UroGen Pharma Ltd. Q2 FY2021 Earnings Call ·
“As mentioned, we recorded net product sales of Jelmyto for the first quarter ended March 31, 2021 of approximately $7.5 million. Although this was a slower start in 2021 than we had initially anticipated, we are optimistic with respect to revenues for the remainder of the year.”
CFO, UroGen Pharma Ltd. Q1 FY2021 Earnings Call ·
“Before I discuss our fourth quarter and year-end 2020 financials, I’d like to touch upon the strategic transaction announced this morning with RTW and provide some details.”
CFO, UroGen Pharma Ltd. Q4 FY2020 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 UroGen Pharma Ltd. (URGN) $434,113 $904,759
2020 UroGen Pharma Ltd. (URGN) $94,269 $1,362,230

Recent activity